Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 9, 2010, Pages 564-570

  Asaka, Naomasa ^a   Kakuo, Hiroyuki ^a   Ohmori, Kouichi ^a   Sasaki, Eiji ^a   Togawa, Michinori ^a   Yamada, Shozo ^a   Oka, Tatsuzo ^b   Kiniwa, Mamoru ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Airway inflammation; Anti inflammatory agent; CAS 223909 92 0; Emesis; Phosphodiesterase 4 inhibitor; TAS 203

Indexed keywords

2 [3 (CYCLOPROPYLMETHOXY) 4 METHOXYPHENYL] 5 (1H 1,2,4-TRIAZOL 1 YL) 1H BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; CILOMILAST; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TAS 203; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRAIN; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DISTRIBUTION; DRUG EFFECT; ENZYME INHIBITION; EOSINOPHIL; EOSINOPHILIA; FERRET; HUMAN; HUMAN CELL; IC 50; INFLAMMATORY CELL; MALE; MONOCYTE; NEUTROPHILIA; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; RESPIRATORY TRACT INFLAMMATION; VOMITING;

EID: 77957681099     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296326     Document Type: Article

References (27)

1. Chung KF. Phosphodiesterase inhibitors in airway disease. Eur J Pharmacol. 2006;533:110-7.
2. Schudt C, Gantner F, Tenors H, Hatzelmann A. Therapeutic potential of selective PDE inhibitors in asthma. Pulm Pharmacol Ther. 1999;12:123-9.
3. Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol. 1999;57:965-73.
4. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci. 1997;18:164-71.
5. Giembycz MA. An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2006;62:138-52.
6. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365:167-75.
7. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lamcet. 2009;9691:685-94.
8. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M. Martinez FJ, et al. Roflumilast in moderate-to severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. Lamcet. 2009;9691:695-703.
9. Huang Z, Ducharme Y, Macdonald D, Robichaud A. The next generation of PDE4 inhibitors. Curr Opin Chem Biol. 2001;5:432-8.
10. Houslay MD, Schafer P, Zhang KY. Phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10:1503-19.
11. Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry. 1989;22:156-60.
12. Christensen SB, Guider A, Forster CJ, Gleason JG, Bender PE, Karpinski JM, et al. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J Med Chem. 1998;41:821-35.
13. Thompson WJ, Terasaki WL, Epstein PM, Strada SJ. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Necleotide Res. 1979;10:69-92.
14. Torphy TJ, Zhou HL, Cieslinski LB. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) upregulates cyclic AMP-specific phosphodiesterase activity. J Pharmacol Exp Ther. 1992;263:1195-205.
15. Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J Pharmacol Exp Ther. 1995;273:674-9.
16. Sabroe I, Conroy DM, Gerard NP, Li Y, Collins PD, Post TW, et al. Cloning and characterization of the guinea pig eosinophil eotaxin receptor, C-C chemokine receptor-3: blockade using a monoclonal antibody in vivo. J Immunol. 1998;161:6139-47.
17. Flø RW, Naess A, Lund-Johansen F, Maehle BO, Sjursen H, Lehmann V, et al. Negative selection of human monocytes using magnetic particles covered by anti-lymphocyte antibodies. J Immunol Methods. 1991;137:89-94.
18. Spina D. PDE4 inhibitors: current status. Br J Pharmacol. 2008;155:308-15.
19. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther. 1999;12:131-5.
20. Alves AC, Pires AL, Cruz HN, Serra MF, Diaz BL, Cordeiro RS, et al. Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. Eur J Pharmacol. 1996;312:89-96.
21. Aoki M, Kobayashi M, Ishikawa J, Saita Y, Terai Y, Takayama K, et al. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7- diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J Pharmacol Exp Ther. 2000;295:255-60.
22. Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, et al. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)-methyl]-1,3,4-oxadiazol-2-yl} -N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity. J Pharmacol Exp Ther. 2009;330:922-31.
23. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001;297:280-90.
24. Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol. 2005;175:1523-31. (Pubitemid 41023053)
25. 2- adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002;110:1045-52.
26. Billah MM, Cooper N, Minnicozzi M, Warneck J, Wang P, Hey JA, et al. Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2- (trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2002;302:127-37.
27. Gale DD, Hofer P, Spina D, Seeds EA, Banner KH, Harrison S, et al. Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294. Pulm Pharmacol Ther. 2003;16:97-104.